Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

about

Clinical and Biological Markers in Hypereosinophilic Syndromes.Imatinib for the treatment of hypereosinophilic syndromes.Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.

P2860

Q49248245-9B8F19C4-1B44-4AC7-823D-719446B8B219 Q50177622-EF39C940-B5D7-46D0-8D0C-8801A46E2F1D Q55022456-688F8C1A-2B76-4475-A24B-76A9F8DDC990

P2860

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

Item

http://www.wikidata.org/entity/Q52912578

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@en

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@nl

type

Item

label

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@en

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@nl

prefLabel

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@en

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@nl

P1476

Imatinib discontinuation for h ...... the FIP1L1-PDGFRA transcript.

@en

P2093

Alina Świderska

http://www.w3.org/2001/XMLSchema#string

Anna Soja

http://www.w3.org/2001/XMLSchema#string

Sławomira Kyrcz-Krzemień

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.

P304

708-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1065983

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marek Hus

Grzegorz Helbig

P577

2015-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26430910

http://www.w3.org/2001/XMLSchema#string

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

about

P2860

P2860

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698